Please complete the CAPTCHA to continue
A concise factual answer block for searchers comparing this professional profile.
Michael Spedding is listed as Secretary General, IUPHAR, and President, Spedding Research Solutions SAS based in Greater Paris Metropolitan Region, France. AeroLeads shows a matched LinkedIn profile for Michael Spedding.
Michael Spedding previously worked as Chairman NC-IUPHAR at The Iuphar/Bps Guide To Pharmacology and Directeur scientifique at Servier. Michael Spedding studied at Durham School, Durham Tech.
Spedding Research Solutions SAS is an independent research company, startd in June 2013, allowing consultancy (in English or French) and research (via coordination of multiple teams ) to yield genuinely original solutions to crucial research (or societal) questions. The key is to find win-win fields of cooperation where the partners are convinced that a major advance can be made, and sufficient resources have been found.Thus using lipidomics we have been able to find that glycosphingolipids (GSLs) are key to denervation in ALS and advance a generic drug to start phase II, in conjunction with J-P Loeffler's lab, and Brad Turner at Florey. Astonishingly, SARS-CoV-2 also modifies GSLs (with Pasteur).We have been associated with ~60 publications since 2013, and MS has an H-index of ~70.A tool is the organisation of high level meetings/symposia to put experts together around a problem.We can employ postdocs in academic labs with high efficiency.No debt in core company, we get the funds then create value.Now Sec Gen International Union of Basic and Clinical Pharmacology, Role in Health care worldwide. Previously, Chairman NC-IUPHAR – classification of all drug sites in the human genome (>80 subcommittees) – reviewed as a crucial activity for human knowledge by UNESCO : www.iuphar-db.org and IUPHAR/BPS Guidetopharmacology.org.Servier responsibility for IMI grant in psychiatry (18Million € each, ~15 partners), Newmeds Experience : 30 years in top level research committees of 3 pharmas. >225 full scientific papers (listed in Pubmed under spedding m), 20+ patents, ~40 compounds into formal preclinical research for multiple indications ; 11 compounds into clinical development, one to market. Contributions to 3 other marketed drugs.ISI Laureate classed among 300 most quoted “French” scientists of all disciplines – 1981-1998 and in 1998-2013. Clarivate highly-cited 2013-2020.French Academy of Pharmacy, 2001; Fellow of British Pharmacological Society, 2005.Set up and run 20,000 m2 new research centre for Servier : neurosciences, drug screening (1992-5), on time.Responsible for Servier for EGIS neuroscience research centre (120 staff), 1995-2011 and 70 PhDs:postdocs funded in universities by Servier (2005-2010); Construction and staffing of SRIMC, a Medicinal Chemistry Research Centre in Budapest (2007-8), in 13 months on time, on budget.Competitive athlete for the last 50 years. 118,000 kms run. Member Club Lotus France – entry level car racing/trackdays, Opel Speedster Turbo. Still getting faster..
Listed skills include Sciences De La Vie, Secteur Pharmaceutique, Neurosciences, Biotechnologie, and 3 others.
A career timeline built from the work history available for this profile.
Hon Prof, Univ Edinburgh
Coordinate 90 subcommittees of 700 scientists around a knowledgebase about the pharmacology of the drug sites expressed by the human genome : the IUPHAR/BPS Guidetopharmacology.org, together with their written output : 100 articles with an h-index of 76.
Suresnes, France
1996 RESEARCH CENTRE DIRECTOR, Croissy, >100 staff; interim director psychopharmacology and molecular pharmacology groups, built/staffed new research centre.1997 DIRECTOR, EXPERIMENTAL SCIENCES, Servier Paris plus Scientific director for EGIS research, Budapest.2004 plus: DEPUTY DIRECTOR of RESEARCH, Coordination of aspects of Servier Discovery research, plus ~60 PhDs and postdocs in universities, several specific projects. Built SRIMC, a med chem centre at Budapest, on time, on budget2010-2013. Scientific Director, DCS Servier: find/analyse innovative science and products for Servier R&D (all therapeutic areas). Report to president R&D and head of business.Previously 1985-1992, Head of Pharmacology and Therapeutic Area Director, Syntex Scotland 1978-1985 Merrell Dow Research Institute, Strasbourg
Édimbourg, Écosse, Royaume-Uni
3 drugs (ranolazine, lifarizine, delequamine) from discovery to end phase II. Ranolazine is marketed for angina by switching ischaemic metabolism in the heart (PDK). The FDA approved totally innovative drug development plans for stroke (lifarizine) and male sexual dysfunction (delequamine; plan subsequently used by Pfizer). Lifarizine showed the best efficacy ever reported in phase II in stroke but we missed an effect on mortality by 1 patient and Roche, who subsequently bought Syntex, stopped the compound. Supported first use of neurotrophin administration for neurodegeneration (Syntex project with F Collins)
Sunderland, Uk
First ATP antagonist screened from 130 isatogens, differentiated ATP/adenosine receptors
Quick answers generated from the profile data available on this page.
Michael Spedding is listed as Secretary General, IUPHAR, and President, Spedding Research Solutions SAS.
Michael Spedding is based in Greater Paris Metropolitan Region, France.
Michael Spedding has worked for The Iuphar/Bps Guide To Pharmacology, Servier, Syntex Research Centre, and Department Of Pharmacology, Sunderland Polytechnic.
You can use AeroLeads to view verified contact signals for Michael Spedding, including work email, phone, and LinkedIn data when available.
Michael Spedding studied at Durham School, Durham Tech.
Michael Spedding is listed with skills including Sciences De La Vie, Secteur Pharmaceutique, Neurosciences, Biotechnologie, Science, Recherche, and Biochimie.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial Search contactsCheck these profiles if this is not the Michael Spedding you were looking for.
